{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:45:22Z","timestamp":1792226722007,"version":"4.4.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T00:00:00Z","timestamp":1594339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Gastroenterol Rep"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s11894-020-00783-1","type":"journal-article","created":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T15:03:51Z","timestamp":1594393431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Cirrhotic Cardiomyopathy"],"prefix":"10.1007","volume":"22","author":[{"given":"Ki Tae","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4431-272X","authenticated-orcid":false,"given":"Samuel S.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,10]]},"reference":[{"issue":"10","key":"783_CR1","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1172\/JCI102813","volume":"32","author":"HJ Kowalski","year":"1953","unstructured":"\u2022\u2022 Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec's cirrhosis. J Clin Invest. 1953;32(10):1025\u201333. The study that ushered in the field of 'cardio-hepatology'. The first study. It also even described QT prolongation.","journal-title":"J Clin Invest"},{"issue":"5","key":"783_CR2","first-page":"530","volume":"151","author":"SS Lee","year":"1989","unstructured":"\u2022\u2022 Lee SS. Cardiac abnormalities in liver cirrhosis. West J Med. 1989;151(5):530\u20135 This review started the field of cirrhotic cardiomyopathy, and coined the term.","journal-title":"West J Med"},{"issue":"2","key":"783_CR3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/hep.510240226","volume":"24","author":"Z Ma","year":"1996","unstructured":"\u2022\u2022 Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology. 1996;24(2):451\u20139. Most cited review; firmly established cirrhotic cardiomyopathy as an important field of study.","journal-title":"Hepatology"},{"issue":"4","key":"783_CR4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/01.CIR.49.4.755","volume":"49","author":"CJ Limas","year":"1974","unstructured":"\u2022 Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation. 1974;49(4):754\u201360. This study, along with the Regans demonstrated abnormal contractility in patients with cirrhosis.","journal-title":"Circulation"},{"issue":"2","key":"783_CR5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI105997","volume":"48","author":"TJ Regan","year":"1969","unstructured":"\u2022\u2022 Regan TJ, Levinson GE, Oldewurtel HA, Frank MJ, Weisse AB, Moschos CB. Ventricular function in noncardiacs with alcoholic fatty liver: role of ethanol in the production of cardiomyopathy. J Clin Invest. 1969;48(2):397\u2013407. This study first described abnormal contractility in patients with alcoholic cirrhosis.","journal-title":"J Clin Invest"},{"issue":"18","key":"783_CR6","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199610313351802","volume":"335","author":"EM Antman","year":"1996","unstructured":"Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335(18):1342\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"783_CR7","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","volume":"61","author":"Y Iwakiri","year":"2014","unstructured":"Iwakiri Y, Shah V, Rockey DC. Vascular pathobiology in chronic liver disease and cirrhosis\u2014current status and future directions. J Hepatol. 2014;61(4):912\u201324.","journal-title":"J Hepatol"},{"issue":"4","key":"783_CR8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3350\/kjhep.2010.16.4.347","volume":"16","author":"MY Kim","year":"2010","unstructured":"Kim MY, Baik SK, Lee SS. Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol. 2010;16(4):347\u201352.","journal-title":"Korean J Hepatol"},{"issue":"3","key":"783_CR9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4254\/wjh.v7.i3.425","volume":"7","author":"H Fukui","year":"2015","unstructured":"Fukui H. Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J Hepatol. 2015;7(3):425\u201342.","journal-title":"World J Hepatol"},{"issue":"4","key":"783_CR10","doi-asserted-by":"crossref","first-page":"H778","DOI":"10.1152\/ajpheart.00749.2019","volume":"318","author":"LC Joseph","year":"2020","unstructured":"Joseph LC, Reyes MV, Lakkadi KR, Gowen BH, Hasko G, Drosatos K, et al. PKCdelta causes sepsis-induced cardiomyopathy by inducing mitochondrial dysfunction. Am J Physiol Heart Circ Physiol. 2020;318(4):H778\u201386.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"783_CR11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jacbts.2019.01.002","volume":"4","author":"H Ueda","year":"2019","unstructured":"Ueda H, Yamaguchi O, Taneike M, Akazawa Y, Wada-Kobayashi H, Sugihara R, et al. Administration of a TLR9 inhibitor attenuates the development and progression of heart failure in mice. JACC Basic Transl Sci. 2019;4(3):348\u201363.","journal-title":"JACC Basic Transl Sci"},{"issue":"4","key":"783_CR12","first-page":"284","volume":"21","author":"F Asgharzadeh","year":"2018","unstructured":"Asgharzadeh F, Bargi R, Beheshti F, Hosseini M, Farzadnia M, Khazaei M. Thymoquinone prevents myocardial and perivascular fibrosis induced by chronic lipopolysaccharide exposure in male rats: thymoquinone and cardiac fibrosis. Aust J Pharm. 2018;21(4):284\u201393.","journal-title":"Aust J Pharm"},{"issue":"5","key":"783_CR13","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0016-5085(00)70180-6","volume":"118","author":"H Liu","year":"2000","unstructured":"\u2022 Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology. 2000;118(5):937\u201344. Demonstrated pathogenic role of NO in cirrhotic cardiomyopathy.","journal-title":"Gastroenterology"},{"issue":"1","key":"783_CR14","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbrc.2016.01.117","volume":"471","author":"H Wu","year":"2016","unstructured":"Wu H, Liu J, Li W, Liu G, Li Z. LncRNA-HOTAIR promotes TNF-alpha production in cardiomyocytes of LPS-induced sepsis mice by activating NF-kappaB pathway. Biochem Biophys Res Commun. 2016;471(1):240\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"783_CR15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cyto.2017.11.015","volume":"107","author":"B Jude","year":"2018","unstructured":"Jude B, Vetel S, Giroux-Metges MA, Pennec JP. Rapid negative inotropic effect induced by TNF-alpha in rat heart perfused related to PKC activation. Cytokine. 2018;107:65\u20139.","journal-title":"Cytokine"},{"issue":"5","key":"783_CR16","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1172\/JCI116834","volume":"92","author":"T Yokoyama","year":"1993","unstructured":"Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest. 1993;92(5):2303\u201312.","journal-title":"J Clin Invest"},{"issue":"23","key":"783_CR17","first-page":"8454","volume":"22","author":"YR Jiang","year":"2018","unstructured":"Jiang YR, Du JY, Wang DD, Yang X. miRNA-130a improves cardiac function by down-regulating TNF-alpha expression in a rat model of heart failure. Eur Rev Med Pharmacol Sci. 2018;22(23):8454\u201361.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"2","key":"783_CR18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jhep.2010.03.011","volume":"53","author":"YY Yang","year":"2010","unstructured":"\u2022 Yang YY, Liu H, Nam SW, Kunos G, Lee SS. Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol. 2010;53(2):298\u2013306. Demonstrated that TNF-alpha is a pathogenic mechanism of cirrhotic cardiomyopathy.","journal-title":"J Hepatol"},{"issue":"11","key":"783_CR19","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1006\/jmcc.1997.0526","volume":"29","author":"U Muller-Werdan","year":"1997","unstructured":"Muller-Werdan U, Schumann H, Fuchs R, Reithmann C, Loppnow H, Koch S, et al. Tumor necrosis factor alpha (TNF alpha) is cardiodepressant in pathophysiologically relevant concentrations without inducing inducible nitric oxide-(NO)-synthase (iNOS) or triggering serious cytotoxicity. J Mol Cell Cardiol. 1997;29(11):2915\u201323.","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"783_CR20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00005344-200201000-00003","volume":"39","author":"GS Friedrichs","year":"2002","unstructured":"Friedrichs GS, Swillo RE, Jow B, Bridal T, Numann R, Warner LM, et al. Sphingosine modulates myocyte electrophysiology, induces negative inotropy, and decreases survival after myocardial ischemia. J Cardiovasc Pharmacol. 2002;39(1):18\u201328.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"783_CR21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrcardio.2017.130","volume":"15","author":"P Pacher","year":"2018","unstructured":"Pacher P, Steffens S, Hasko G, Schindler TH, Kunos G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat Rev Cardiol. 2018;15(3):151\u201366.","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"783_CR22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/cvr\/cvp369","volume":"85","author":"P Mukhopadhyay","year":"2010","unstructured":"Mukhopadhyay P, Rajesh M, Batkai S, Patel V, Kashiwaya Y, Liaudet L, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res. 2010;85(4):773\u201384.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"783_CR23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1042\/CS20130642","volume":"127","author":"SW Nam","year":"2014","unstructured":"\u2022 Nam SW, Liu H, Wong JZ, Feng AY, Chu G, Merchant N, et al. Cardiomyocyte apoptosis contributes to pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated mice. Clin Sci (Lond). 2014;127(8):519\u201326. Showed role of cardiac apoptosis in pathogenesis.","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"783_CR24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2337\/db11-0477","volume":"61","author":"M Rajesh","year":"2012","unstructured":"Rajesh M, Batkai S, Kechrid M, Mukhopadhyay P, Lee WS, Horvath B, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes. 2012;61(3):716\u201327.","journal-title":"Diabetes"},{"key":"783_CR25","doi-asserted-by":"crossref","unstructured":"Schaich CL, Shaltout HA, Brosnihan KB, Howlett AC, Diz DI. Acute and chronic systemic CB1 cannabinoid receptor blockade improves blood pressure regulation and metabolic profile in hypertensive (mRen2)27 rats. Physiol Rep. 2014;2(8).","DOI":"10.14814\/phy2.12108"},{"issue":"6","key":"783_CR26","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.01.021","volume":"62","author":"SA Gaskari","year":"2015","unstructured":"\u2022 Gaskari SA, Liu H, D\u2019Mello C, Kunos G, Lee SS. Blunted cardiac response to hemorrhage in cirrhotic rats is mediated by local macrophage-released endocannabinoids. J Hepatol. 2015;62(6):1272\u20137. Showed that fragility to hypotensive hemorrhage is mediated via endocannabinoids.","journal-title":"J Hepatol"},{"issue":"1","key":"783_CR27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bpg.2006.06.003","volume":"21","author":"RF Lee","year":"2007","unstructured":"Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21(1):125\u201340.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"3 Pt 1","key":"783_CR28","first-page":"481","volume":"12","author":"SS Lee","year":"1990","unstructured":"\u2022\u2022 Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology. 1990;12(3 Pt 1):481\u20135. First mechanistic pathogenic study of cirrhotic cardiomyopathy in a rat model.","journal-title":"Hepatology"},{"issue":"6","key":"783_CR29","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/lt.24768","volume":"23","author":"H Liu","year":"2017","unstructured":"\u2022 Liu H, Jayakumar S, Traboulsi M, Lee SS. Cirrhotic cardiomyopathy: implications for liver transplantation. Liver Transpl. 2017;23(6):826\u201335. Reviewed role of cirrhotic cardiomyopathy in the transplant process.","journal-title":"Liver Transpl"},{"issue":"1","key":"783_CR30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/hep.30875","volume":"71","author":"M Izzy","year":"2020","unstructured":"\u2022\u2022 Izzy M, Van Wagner LB, Lin G, Altieri M, Findlay JY, Oh JK, et al. Cirrhotic cardiomyopathy C: redefining cirrhotic cardiomyopathy for the modern era. Hepatology. 2020;71(1):334\u201345. Redefined new cirrhotic cardiomyopathy diagnostic criteria.","journal-title":"Hepatology"},{"issue":"22","key":"783_CR31","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1161\/CIRCULATIONAHA.106.647172","volume":"116","author":"TP Abraham","year":"2007","unstructured":"Abraham TP, Dimaano VL, Liang HY. Role of tissue Doppler and strain echocardiography in current clinical practice. Circulation. 2007;116(22):2597\u2013609.","journal-title":"Circulation"},{"issue":"5","key":"783_CR32","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10741-016-9552-9","volume":"21","author":"S Moller","year":"2016","unstructured":"Moller S, Wiese S, Halgreen H, Hove JD. Diastolic dysfunction in cirrhosis. Heart Fail Rev. 2016;21(5):599\u2013610.","journal-title":"Heart Fail Rev"},{"issue":"32","key":"783_CR33","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.3748\/wjg.v25.i32.4779","volume":"25","author":"I Stundiene","year":"2019","unstructured":"Stundiene I, Sarnelyte J, Norkute A, Aidietiene S, Liakina V, Masalaite L, et al. Liver cirrhosis and left ventricle diastolic dysfunction: systematic review. World J Gastroenterol. 2019;25(32):4779\u201395.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"783_CR34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hep.510270106","volume":"27","author":"M Bernardi","year":"1998","unstructured":"\u2022 Bernardi M, Calandra S, Colantoni A, Trevisani F, Raimondo ML, Sica G, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27(1):28\u201334. First large-sample clinical study showing correlation of long QTc and stage of cirrhosis.","journal-title":"Hepatology"},{"issue":"4","key":"783_CR35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0168-8278(02)00010-7","volume":"36","author":"JH Henriksen","year":"2002","unstructured":"\u2022 Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol. 2002;36(4):513\u201320. Description of electromechanical dyssynchrony.","journal-title":"J Hepatol"},{"issue":"2","key":"783_CR36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/gut.49.2.268","volume":"49","author":"F Wong","year":"2001","unstructured":"\u2022\u2022 Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut. 2001;49(2):268\u201375. First demonstration of chronotropic incompetence.","journal-title":"Gut"},{"issue":"1","key":"783_CR37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1540-8167.2006.00622.x","volume":"18","author":"A Zambruni","year":"2007","unstructured":"\u2022\u2022 Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol. 2007;18(1):77\u201382. Showed that Friedericia method of QT correction is superior for cirrhosis.","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"1","key":"783_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1586\/egh.11.86","volume":"6","author":"M Bernardi","year":"2012","unstructured":"\u2022 Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol. 2012;6(1):57\u201366. Excellent discussion of possible relevance of QTc prolongation in cirrhosis.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"2 Pt 1","key":"783_CR39","first-page":"G537","volume":"273","author":"CA Ward","year":"1997","unstructured":"\u2022 Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol. 1997;273(2 Pt 1):G537\u201344. Showed that QTc prolongation is due to abnormal function of two types of K+channels in a rat model.","journal-title":"Am J Physiol"},{"issue":"42","key":"783_CR40","doi-asserted-by":"crossref","first-page":"15492","DOI":"10.3748\/wjg.v20.i42.15492","volume":"20","author":"N Gassanov","year":"2014","unstructured":"Gassanov N, Caglayan E, Semmo N, Massenkeil G, Er F. Cirrhotic cardiomyopathy: a cardiologist's perspective. World J Gastroenterol. 2014;20(42):15492\u20138.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"783_CR41","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/10408363.2018.1460576","volume":"55","author":"A Piek","year":"2018","unstructured":"Piek A, Du W, de Boer RA, Sillje HHW. Novel heart failure biomarkers: why do we fail to exploit their potential? Crit Rev Clin Lab Sci. 2018;55(4):246\u201363.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"3","key":"783_CR42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ejheart.2004.01.003","volume":"6","author":"M Richards","year":"2004","unstructured":"Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail. 2004;6(3):351\u20134.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"783_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7888\/juoeh.42.1","volume":"42","author":"Y Nabeshima","year":"2020","unstructured":"Nabeshima Y, Sakanishi Y, Otani K, Higa Y, Honda M, Otsuji Y, et al. Estimation of B-type natriuretic peptide values from N-terminal proBNP levels. J UOEH. 2020;42(1):1\u201312.","journal-title":"J UOEH"},{"issue":"1","key":"783_CR44","first-page":"23","volume":"9","author":"B Sezgin","year":"2019","unstructured":"Sezgin B, Cindoglu C, Uyanikoglu A, Yenice N. Association of cirrhosis and cardiomyopathy. Euroasian J Hepatogastroenterol. 2019;9(1):23\u20136.","journal-title":"Euroasian J Hepatogastroenterol"},{"issue":"2","key":"783_CR45","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.19082\/1984","volume":"8","author":"A Metwaly","year":"2016","unstructured":"Metwaly A, Khalik AA, Nasr FM, Sabry AI, Gouda MF, Hassan M. Brain natriuretic peptide in liver cirrhosis and fatty liver: correlation with cardiac performance. Electron Physician. 2016;8(2):1984\u201393.","journal-title":"Electron Physician"},{"issue":"2","key":"783_CR46","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.amjms.2017.04.005","volume":"354","author":"J Zhao","year":"2017","unstructured":"\u2022 Zhao J, Li S, Ren L, Guo X, Qi X. Pro-brain natriuretic peptide and troponin T-hypersensitivity levels correlate with the severity of liver dysfunction in liver cirrhosis. Am J Med Sci. 2017;354(2):131\u20139. Suggested usefulness of both troponin T and pro-BNP as predictive biomarkers.","journal-title":"Am J Med Sci"},{"issue":"4","key":"783_CR47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.5152\/tjg.2016.16100","volume":"27","author":"WA Abbas","year":"2016","unstructured":"Abbas WA, Kasem Ahmed SM, Abdel Aal AM, Mahmoud AA, Abdelmalek MO, Mekky MA, et al. Galactin-3 and brain natriuretic peptide versus conventional echocardiography in the early detection of cirrhotic cardiomyopathy. Turk J Gastroenterol. 2016;27(4):367\u201374.","journal-title":"Turk J Gastroenterol"},{"issue":"4","key":"783_CR48","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3343\/alm.2018.38.4.306","volume":"38","author":"U Ansari","year":"2018","unstructured":"Ansari U, Behnes M, Hoffmann J, Natale M, Fastner C, El-Battrawy I, et al. Galectin-3 reflects the echocardiographic grades of left ventricular diastolic dysfunction. Ann Lab Med. 2018;38(4):306\u201315.","journal-title":"Ann Lab Med"},{"issue":"5","key":"783_CR49","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1432-2277.2011.01219.x","volume":"24","author":"FH Saner","year":"2011","unstructured":"\u2022 Saner FH, Neumann T, Canbay A, Treckmann JW, Hartmann M, Goerlinger K, et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int. 2011;24(5):425\u201332. Suggested predictive utility of BNP.","journal-title":"Transpl Int"},{"issue":"11","key":"783_CR50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1753944717727498","volume":"11","author":"C Zivlas","year":"2017","unstructured":"Zivlas C, Triposkiadis F, Psarras S, Giamouzis G, Skoularigis I, Chryssanthopoulos S, et al. Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3. Ther Adv Cardiovasc Dis. 2017;11(11):283\u201395.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"1","key":"783_CR51","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hfc.2017.08.009","volume":"14","author":"C Gehlken","year":"2018","unstructured":"Gehlken C, Suthahar N, Meijers WC, de Boer RA. Galectin-3 in heart failure: an update of the last 3\u00a0years. Heart Fail Clin. 2018;14(1):75\u201392.","journal-title":"Heart Fail Clin"},{"issue":"2","key":"783_CR52","first-page":"1322","volume":"19","author":"R Han","year":"2020","unstructured":"Han R, Li K, Li L, Zhang L, Zheng H. Expression of microRNA-214 and galectin-3 in peripheral blood of patients with chronic heart failure and its clinical significance. Exp Ther Med. 2020;19(2):1322\u20138.","journal-title":"Exp Ther Med"},{"issue":"6","key":"783_CR53","first-page":"669","volume":"45","author":"M Gudowska","year":"2015","unstructured":"Gudowska M, Gruszewska E, Cylwik B, Panasiuk A, Rogalska M, Flisiak R, et al. Galectin-3 concentration in liver diseases. Ann Clin Lab Sci. 2015;45(6):669\u201373.","journal-title":"Ann Clin Lab Sci"},{"key":"783_CR54","first-page":"110773","volume":"62","author":"H Liu","year":"2015","unstructured":"Liu H, Lee SS. Elevated galectin-3 in cirrhotic heart increases TNF\u03b1 and inhibits cardiac contractility in rats. Abstract. Hepatology. 2015;62:110773.","journal-title":"Hepatology"},{"issue":"4","key":"783_CR55","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/clinchem\/hvaa023","volume":"66","author":"MN Lyngbakken","year":"2020","unstructured":"Lyngbakken MN, Aagaard EN, Kvisvik B, Berge T, Pervez MO, Brynildsen J, et al. Cardiac troponin I and T are associated with left ventricular function and structure: data from the Akershus cardiac examination 1950 study. Clin Chem. 2020;66(4):567\u201378.","journal-title":"Clin Chem"},{"issue":"16","key":"783_CR56","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1161\/CIRCULATIONAHA.117.027681","volume":"135","author":"M Gori","year":"2017","unstructured":"Gori M, Senni M, Metra M. High-sensitive cardiac troponin for prediction of clinical heart failure: are we ready for prime time? Circulation. 2017;135(16):1506\u20138.","journal-title":"Circulation"},{"issue":"2","key":"783_CR57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/jgh.13902","volume":"33","author":"M Elnegouly","year":"2018","unstructured":"Elnegouly M, Umgelter K, Safi W, Hapfelmeier A, Schmid RM, Umgelter A. Elevated cardiac troponin T in cirrhotic patients with emergency care admissions: associations with mortality. J Gastroenterol Hepatol. 2018;33(2):518\u201323.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"783_CR58","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1053\/jhep.2003.50447","volume":"38","author":"L Ruiz-del-Arbol","year":"2003","unstructured":"\u2022\u2022 Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology. 2003;38(5):1210\u20138. First study to suggest role of cardiac dysfunction in pathogenesis of hepatorenal syndrome after spontaneous bacterial peritonitis.","journal-title":"Hepatology"},{"issue":"5","key":"783_CR59","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1053\/jhep.2003.50489","volume":"38","author":"SS Lee","year":"2003","unstructured":"Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology. 2003;38(5):1089\u201391.","journal-title":"Hepatology"},{"issue":"4","key":"783_CR60","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cld.2019.06.002","volume":"23","author":"D Adebayo","year":"2019","unstructured":"Adebayo D, Neong SF, Wong F. Ascites and hepatorenal syndrome. Clin Liver Dis. 2019;23(4):659\u201382.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"783_CR61","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jhep.2012.08.027","volume":"58","author":"A Nazar","year":"2013","unstructured":"\u2022 Nazar A, Guevara M, Sitges M, Terra C, Sola E, Guigou C, et al. Left ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58(1):51\u20137. Renal impairment correlated with diastolic dysfunction.","journal-title":"J Hepatol"},{"issue":"5","key":"783_CR62","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/hep.30040","volume":"68","author":"M Izzy","year":"2018","unstructured":"Izzy M, Oh J, Watt KD. Cirrhotic cardiomyopathy after transplantation: neither the transient nor innocent bystander. Hepatology. 2018;68(5):2008\u201315.","journal-title":"Hepatology"},{"issue":"1","key":"783_CR63","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12882-018-1039-6","volume":"19","author":"AD Fialla","year":"2018","unstructured":"Fialla AD, Schaffalitzky de Muckadell OB, Bie P, Thiesson HC. Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretion. BMC Nephrol. 2018;19(1):238.","journal-title":"BMC Nephrol"},{"issue":"2","key":"783_CR64","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/jvim.15454","volume":"33","author":"MK Ames","year":"2019","unstructured":"Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019;33(2):363\u201382.","journal-title":"J Vet Intern Med"},{"issue":"3","key":"783_CR65","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1134\/S000629791903009X","volume":"84","author":"AA Khudiakov","year":"2019","unstructured":"Khudiakov AA, Smolina NA, Perepelina KI, Malashicheva AB, Kostareva AA. Extracellular microRNAs and mitochondrial DNA as potential biomarkers of arrhythmogenic cardiomyopathy. Biochemistry (Mosc). 2019;84(3):272\u201382.","journal-title":"Biochemistry (Mosc)"},{"issue":"4","key":"783_CR66","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.30916","volume":"71","author":"C Matyas","year":"2020","unstructured":"Matyas C, Erdelyi K, Trojnar E, Zhao S, Varga ZV, Paloczi J, et al. Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signaling in an experimental model of hepatic cardiomyopathy. Hepatology. 2020;71(4):1391\u2013407.","journal-title":"Hepatology"},{"issue":"8","key":"783_CR67","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/MEG.0000000000001128","volume":"30","author":"OM Silvestre","year":"2018","unstructured":"\u2022\u2022 Silvestre OM, Farias AQ, Ramos DS, Furtado MS, Rodrigues AC, Ximenes RO, et al. Beta-blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial. Eur J Gastroenterol Hepatol. 2018;30(8):930\u20137. First RCT of potential therapy, 6 months of beta-blocker, in cirrhotic cardiomyopathy. Negative study, but authors suggested that a longer duration may be needed.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"783_CR68","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jhep.2003.10.026","volume":"40","author":"JH Henriksen","year":"2004","unstructured":"\u2022 Henriksen JH, Bendtsen F, Hansen EF, Moller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol. 2004;40(2):239\u201346. 90\u00a0min beta-blockade corrected the prolonged QTc.","journal-title":"J Hepatol"},{"issue":"3","key":"783_CR69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jhep.2007.11.012","volume":"48","author":"A Zambruni","year":"2008","unstructured":"\u2022 Zambruni A, Trevisani F, Di Micoli A, Savelli F, Berzigotti A, Bracci E, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol. 2008;48(3):415\u201321. Beta-blockade of 1\u20133\u00a0months duration also shortened the Qtc interval but only using the Bazett method of correction.","journal-title":"J Hepatol"},{"issue":"1","key":"783_CR70","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2017.02.005","volume":"67","author":"R Sinha","year":"2017","unstructured":"\u2022 Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017;67(1):40\u20136. Retrospective study suggested possible usefulness of carvedilol in cirrhotic cardiomyopathy.","journal-title":"J Hepatol"},{"key":"783_CR71","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Premkumar M, Rangegowda D, Vyas T, Khumuckham JS, Shasthry SM, Thomas SS, et al. Carvedilol combined with ivabradine improves left ventricular diastolic dysfunction, clinical progression, and survival in cirrhosis. J Clin Gastroenterol. 2019. Important RCT showed that carvedilol combined with ivabradine improved diastolic dysfunction and survival compared to control group.","DOI":"10.1097\/MCG.0000000000001219"},{"key":"783_CR72","doi-asserted-by":"crossref","unstructured":"\u2022 Koshy AN, Gow PJ, Han HC, Teh AW, Jones R, Testro A, et al. Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30\u00a0years. Eur Heart J Qual Care Clin Outcomes. 2020. Excellent review of CV mortality after liver transplantation.","DOI":"10.1093\/ehjqcco\/qcaa009"},{"issue":"1","key":"783_CR73","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jhep.2004.09.008","volume":"42","author":"M Torregrosa","year":"2005","unstructured":"\u2022 Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42(1):68\u201374. First study examining cardiac function and reversibility after liver transplantation.","journal-title":"J Hepatol"},{"issue":"9","key":"783_CR74","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/ctr.12778","volume":"30","author":"A Sonny","year":"2016","unstructured":"Sonny A, Ibrahim A, Schuster A, Jaber WA, Cywinski JB. Impact and persistence of cirrhotic cardiomyopathy after liver transplantation. Clin Transpl. 2016;30(9):986\u201393.","journal-title":"Clin Transpl"},{"issue":"6","key":"783_CR75","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/hep.29329","volume":"66","author":"LB Van Wagner","year":"2017","unstructured":"\u2022\u2022 Van Wagner LB, Ning H, Whitsett M, Levitsky J, Uttal S, Wilkins JT, et al. A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: the CAR-OLT score. Hepatology. 2017;66(6):1968\u201379. Validation of points-based system to predict cardiovascular events after transplantation.","journal-title":"Hepatology"}],"container-title":["Current Gastroenterology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-020-00783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11894-020-00783-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11894-020-00783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:30:38Z","timestamp":1625877038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11894-020-00783-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,10]]},"references-count":75,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["783"],"URL":"https:\/\/doi.org\/10.1007\/s11894-020-00783-1","relation":{},"ISSN":["1522-8037","1534-312X"],"issn-type":[{"value":"1522-8037","type":"print"},{"value":"1534-312X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,10]]},"assertion":[{"value":"10 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All reported studies\/experiments with human or animal subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance With Ethical Standards"}},{"value":"The authors declared that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"45"}}